Gliatamine for the migraineurs with cognitive complaint

Not Applicable

Active, not recruiting

• Conditions: Diseases of the nervous system

• Registration Number: KCT0004659
• Lead Sponsor: Seoul National University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

Patients with migraine headaches in need of prophylaxis who meet all of the following criteria may participate in this clinical trial.
1. Whom agrees to participate in the study
2. Adults 19 – 85 years old
3. Those who meet the ICHD-III beta migraine diagnostic criteria and complain of cognitive decline
* Those who complain of cognitive decline
Are not dementia due to mild cognitive impairment (MCI) and have an MMSE of 22 to 26 or less
-Patients with subjective memory disorder” complain of memory disorder even though normal on cognitive function test and not mild cognitive impairment or dementia
4. Who can read and understand the questionnaire?
5. For women of childbearing age who are taking appropriate contraception or who are negative on a pregnancy test.

Exclusion Criteria

1. Subjects suspected of having drug withdrawal due to headache seizures during baseline or evaluation
2. First-time migraine sufferers at age 50 or older.
3. Subjects with advanced neurological disease
4. Subjects with renal or hepatic insufficiency (patients whose blood creatinine, AST, ALT, and total bilirubin levels are at least 1.5 times the upper limit of normal)
5. Subjects with severe cardiovascular disease
6. Subjects with hypersensitivity to glycatamine
7. Pregnant and lactating women
8. Subjects who participate in other clinical trials under research and development
9. If the researcher judges that participation in this study poses a threat to the well-being of the subject or results in an unreliable evaluation at the end of the study.
10. Subjects with a history of peptic ulcer
11. Subjects with a history of allergies to NSAIDs
12. Subjects who received migraine prophylaxis within the last 4 weeks (including propranolol, sibelium, verapamil, tricyclic antidepressant, valproic acid, topiramate, gabapentin)
13. Subjects with a history of alcohol and drug abuse.

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Korean-Mini-Mental State Examination (K-MMSE)

Secondary Outcome Measures

Name	Time	Method
MIDAS (Migraine Disability Assessment)